Literature DB >> 2724138

Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans.

T A Baillie1, W J Adams, D G Kaiser, L S Olanoff, G W Halstead, H Harpootlian, G J Van Giessen.   

Abstract

The metabolic chiral inversion of R-(-)-ibuprofen has been studied in human subjects by means of specific deuterium labeling and stereoselective gas chromatography-mass spectrometry methodology. After simultaneous p.o. administration of a mixture of R-(-)-ibuprofen (300 mg) and R-(-)-[3,3,3-2H3]ibuprofen (304 mg) to four adult male volunteers, the enantiomeric composition and deuterium content of the drug in serum, and of the drug and its principal metabolites in urine, were followed over a period of 24 hr. The results of these analyses indicated that: 1) conversion of R-(-)- to S-(+)-ibuprofen takes place with complete retention of deuterium at the beta-methyl (C-3) position; 2) chiral inversion of R-(-)-[2H3]ibuprofen is not subject to a discernible deuterium isotope effect; and 3) replacement of the beta-methyl hydrogen atoms by deuterium has no effect on any of the serum pharmacokinetic parameters for R-(-)- or S-(+)-ibuprofen. These data indicate that the process whereby R-(-)-ibuprofen undergoes metabolic inversion in human subjects does not involve 2,3-dehydroibuprofen as an intermediate, and that the underlying mechanism cannot, therefore, entail a desaturation/reduction sequence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724138

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

3.  Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.

Authors:  G Li; G Treiber; K Maier; S Walker; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

4.  Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis.

Authors:  G Geisslinger; K P Stock; D Loew; G L Bach; K Brune
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

5.  Use of stable isotopes for evaluation of drug delivery systems: comparison of ibuprofen release in vivo and in vitro from two biphasic release formulations utilizing different rate-controlling polymers.

Authors:  D L Theis; L J Lucisano; G W Halstead
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

6.  Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen.

Authors:  B Gabard; G Nirnberger; H Schiel; H Mascher; C Kikuta; J M Mayer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

8.  Pharmacokinetics of tiaprofenic acid in normal rabbits and rabbits subjected to joint immobilisation.

Authors:  I Meyer-Carrive; G G Graham; P Ghosh
Journal:  Agents Actions       Date:  1993-05

9.  The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.

Authors:  P Seideman; F Lohrer; G G Graham; M W Duncan; K M Williams; R O Day
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

10.  Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans.

Authors:  K M Knights; C F McLean; A L Tonkin; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.